Compare ACCL & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCL | HOTH |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 15.8M |
| IPO Year | 2025 | 2019 |
| Metric | ACCL | HOTH |
|---|---|---|
| Price | $1.40 | $1.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 2.3M | 855.2K |
| Earning Date | 03-03-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.91 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $4,888,824.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.25 | ★ N/A |
| Revenue Growth | ★ 11.91 | N/A |
| 52 Week Low | $1.23 | $0.66 |
| 52 Week High | $5.00 | $2.12 |
| Indicator | ACCL | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 29.97 | 54.55 |
| Support Level | $1.35 | $0.77 |
| Resistance Level | $1.69 | $1.06 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 34.80 | 84.06 |
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).